This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2026 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.90% per year. These returns cover a period from January 1, 1988 through December 1, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
biotechs: Archive
Amgen Strikes Drug Pricing Deal With Trump: What Investors Should Know
by Sundeep Ganoria
AMGN signs a pricing deal with the Trump administration, cutting U.S. drug costs, expanding DTC access and securing tariff relief tied to domestic investment.
GSKNegative Net Change BMYNegative Net Change MRKPositive Net Change AMGNNegative Net Change
biotechs medical pharmaceuticals
Sanofi to Buy Dynavax for $2.2B to Boost Adult Vaccine Franchise
by Zacks Equity Research
SNY's $2.2 billion deal for Dynavax adds Heplisav-B, a shingles candidate, and other vaccine programs, strengthening its adult vaccine franchise and pipeline.
SNYNegative Net Change DVAXNo Net Change CRMDNegative Net Change CSTLNegative Net Change
biotechnology biotechs medical pharmaceuticals vaccines
Will the Recent Pricing Deal With the Government Impact BMY's Sales?
by Ekta Bagri
BMY has agreed to supply Eliquis free of charge to Medicaid starting in 2026 and will also donate seven tons of the active pharmaceutical ingredient used in Eliquis.
BMYNegative Net Change JNJNegative Net Change PFEPositive Net Change MRKPositive Net Change
biotechnology biotechs medical pharmaceuticals
ABBV vs. AZN: Which Pharma Stock is the Better Investment Now?
by Sundeep Ganoria
AbbVie and AstraZeneca both bring blockbuster drugs, deep pipelines and risks, but their growth paths, pressures and priorities now sharply diverge.
AZNNegative Net Change ABBVNegative Net Change
biotechs medical pharmaceuticals vaccines
Novo Nordisk Wins FDA Nod for Oral Wegovy in Obesity, Stock Up
by Zacks Equity Research
NVO stock up as it wins FDA approval for oral Wegovy in obesity, becoming the first oral GLP-1 RA indicated for weight management.
NVOPositive Net Change LLYNegative Net Change VKTXNegative Net Change GPCRPositive Net Change
biotechnology biotechs medical pharmaceuticals
GILD Exercises Option to License Assembly Bio's Herpes Programs
by Zacks Equity Research
Gilead exercises its option to license ASMB's HSV programs for developing long-acting candidates, ABI-1179 & ABI-5366, for recurrent genital herpes.
GILDNegative Net Change CRMDNegative Net Change ASMBPositive Net Change CSTLNegative Net Change
biotechs
CRSP Stock Rises on Encouraging Early Data From Zugo-Cel Studies
by Zacks Equity Research
CRISPR Therapeutics shares jump after early zugo-cel study data show sustained B-cell depletion and early efficacy across autoimmune and cancer studies.
LLYNegative Net Change CRMDNegative Net Change CRSPNegative Net Change CSTLNegative Net Change
biotechs
JNJ's Tremfya Gets EU Approval for Pediatric Plaque Psoriasis
by Zacks Equity Research
Johnson & Johnson wins EU approval for Tremfya in pediatric plaque psoriasis, making it the first IL-23 inhibitor cleared for any pediatric condition.
JNJNegative Net Change ANIPPositive Net Change CRMDNegative Net Change CSTLNegative Net Change
biotechs medical
Novo Nordisk vs. Amgen: Which Healthcare Stock Is the Smarter Choice?
by Ahan Chakraborty
NVO and AMGN square off as GLP-1 leadership, pipeline depth, and diversification set up a compelling healthcare stock comparison.
NVOPositive Net Change LLYNegative Net Change AMGNNegative Net Change
biotechnology biotechs medical oncology-screening pharmaceuticals
5 Big Drug Stocks That May Continue to Outperform in 2026
by Kinjel Shah
Five big drugmakers, including LLY and JNJ, are riding innovation, dealmaking and pipeline momentum that could help them keep outperforming in 2026.
AZNNegative Net Change JNJNegative Net Change LLYNegative Net Change AMGNNegative Net Change ABBVNegative Net Change
biotechs pharmaceuticals
J&J Wins FDA Nod for Subcutaneous Version of NSCLC Drug Rybrevant (Revised)
by Zacks Equity Research
JNJ wins FDA approval for a subcutaneous version of Rybrevant, cutting treatment time to minutes and boosting convenience across NSCLC indications.
AZNNegative Net Change JNJNegative Net Change HALONegative Net Change
biotechs medical pharmaceuticals
AZN, Daiichi's Enhertu Gets FDA Nod for First-Line Breast Cancer (Revised)
by Zacks Equity Research
AstraZeneca's Enhertu wins FDA nod as a first-line treatment for HER2-positive metastatic breast cancer.
AZNNegative Net Change ANIPPositive Net Change CRMDNegative Net Change CSTLNegative Net Change
biotechs
BioMarin to Buy Rare Disease Drugmaker Amicus Therapeutics for $4.8B
by Zacks Equity Research
BMRN agrees to acquire FOLD for $4.8B, adding two growing rare disease drugs and a late-stage pipeline asset to its portfolio.
BMRNNegative Net Change FOLDNegative Net Change ANIPPositive Net Change CRMDNegative Net Change
biotechs medical
AZN, Daiichi's Enhertu Gets Breakthrough Tag for Expanded Cancer Use
by Zacks Equity Research
AstraZeneca's Enhertu wins FDA Breakthrough tag for expanded use in breast cancer, while a late-stage study on ceralasertib + Imfinzi in lung cancer misses its goal.
AZNNegative Net Change ANIPPositive Net Change CRMDNegative Net Change CSTLNegative Net Change
biotechs
What Awaits These 4 Biotech Stocks That More Than Doubled in 2025
by Ahan Chakraborty
IONS, GPCR, MNPR and KOD more than double in 2025 as policy clarity, M&A revival and clinical wins lift biotech momentum into 2026.
IONSNegative Net Change KODNegative Net Change MNPRNegative Net Change GPCRPositive Net Change
biotechnology biotechs medical pharmaceuticals
Cytokinetics Wins FDA Approval for Cardiovascular Drug, Stock up
by Zacks Equity Research
CYTK enters a new era as FDA approval of Myqorzo transforms it into a commercial biotech, opening a long-term growth runway in cardiology.
BMYNegative Net Change FOLDNegative Net Change CYTKNegative Net Change CRMDNegative Net Change
biotechnology biotechs medical pharmaceuticals
Drug Sector on a High as 9 Drugmakers Strike Drug Pricing Deals
by Sundeep Ganoria
Amgen and eight other pharma giants struck deals with the Trump administration to cut U.S. drug prices while gaining tariff relief and manufacturing incentives.
GSKNegative Net Change BMYNegative Net Change MRKPositive Net Change AMGNNegative Net Change GILDNegative Net Change
biotechs medical pharmaceuticals
3 Biotech Stocks Wall Street Analysts Are Bullish on for 2026
by Ekta Bagri
EyePoint, ANI Pharmaceuticals and Tango Therapeutics put up a stellar show in 2025 and are set to carry the momentum in 2026 as well.
ANIPPositive Net Change EYPTNegative Net Change TNGXNegative Net Change
biotechnology biotechs medical pharmaceuticals
MRNA to Get CEPI Funding for Phase III Study on Pandemic Influenza Jab
by Zacks Equity Research
Moderna secures up to $54.3 million from CEPI to fund a pivotal phase III study of its mRNA-based H5 pandemic flu vaccine candidate, mRNA-1018.
MRNANegative Net Change ANIPPositive Net Change CRMDNegative Net Change CSTLNegative Net Change
biotechs
Novo Nordisk Files NDA for Next-Generation Obesity Drug CagriSema
by Zacks Equity Research
NVO files an NDA with the FDA for once-weekly CagriSema, a combo obesity injection showing superior weight loss in obese patients in phase III studies.
NVOPositive Net Change LLYNegative Net Change CRMDNegative Net Change CSTLNegative Net Change
biotechnology biotechs medical pharmaceuticals
Will GILD's Strong HIV Portfolio Reap Rewards in 2026?
by Ekta Bagri
GILD???s HIV franchise gains momentum as twice-yearly PrEP Yeztugo wins FDA approval and late-stage data back a new single-tablet regimen.
GSKNegative Net Change MRKPositive Net Change GILDNegative Net Change
biotechnology biotechs medical pharmaceuticals
J&J Wins FDA Nod for Subcutaneous Version of NSCLC Drug Rybrevant
by Zacks Equity Research
JNJ wins FDA approval for a subcutaneous version of Rybrevant, cutting treatment time to minutes and boosting convenience across NSCLC indications.
AZNNegative Net Change JNJNegative Net Change HALONegative Net Change
biotechs medical pharmaceuticals
SNY's Rare Disease Drug Efdoralprin Alfa Gets EMA's Orphan Drug Tag
by Zacks Equity Research
Sanofi gains EMA Orphan Drug status for efdoralprin alfa, a phase II biologic for AATD-related emphysema with promising dosing data.
SNYNegative Net Change ANIPPositive Net Change CRMDNegative Net Change CSTLNegative Net Change
biotechs medical
Will Strong Livmarli Uptake Continue to Aid MIRM's Revenues in 2026?
by Zacks Equity Research
Mirum's Livmarli sales surge 70% in the first nine months of 2025. Expanding approvals and commercialization are set to fuel revenue momentum into 2026.
GSKNegative Net Change MIRMNegative Net Change TVTXNegative Net Change
biotechs
Can Higher-Dose Wegovy Help Novo Nordisk Regain Obesity Market Share?
by Ahan Chakraborty
NVO seeks approval for a 7.2 mg Wegovy dose after study data showed stronger weight loss that can challenge Zepbound's U.S. momentum.
NVOPositive Net Change LLYNegative Net Change VKTXNegative Net Change
biotechnology biotechs medical pharmaceuticals